TNFRSF9 and neoplasm: Many of these patients had disease that progressed on treatment with immune checkpoint inhibitors, thereby providing an opportunity to test the hypothesis that 4-1BB/CD137 agonists could convert weak or dysfunctional antitumor immune responses to tumor-controlling immunity.